Relationship Between Cognition, Workforce Participation and Well-Being in Individuals With Multiple Sclerosis

NCT07211516 | Not Yet Recruiting

• 1 other identifier: MSCogWork2
• Study Type: observational
• Target: 75
• Locations: 1 country
• Sites: 1

Brief Summary

Multiple sclerosis (MS) is a chronic neurodegenerative disease and a leading cause of reduced workforce participation due to neurological illness in Western countries. Over the past 30 years, new treatments have reduced symptom burden, allowing patients to stay in the workforce longer. However, fatigue and cognitive impairments remain major barriers to work capacity. This project aims to examine factors important for work ability and well-being in persons with MS and cognitive impairments. The specific research questions are:

1. 1.How do job type and opportunities for workplace adaptations influence work ability and well-being in individuals with MS and cognitive impairments?
2. 2.What are the associations between cognitive function in MS and work ability as well as well-being? The investigators plan to collect data on patients with MS who have undergone a neuropsychological assessment at the neurology clinic in Region Gävleborg over a five year period. Approximately 100 patients are eligible for participation. Data will be collected through surveys and by extracting information from medical records. The surveys include questions related to well-being and work ability. Data from medical records contain data from the neuropsychological assessment, other rehabilitation interventions as well as data related to treatment and progress of MS.

Conditions

Multiple Sclerosis

Outcome Measures

Primary Outcomes (4)

• Work participation

  Percentage of full-time work. 100 % full-time work and 0% is not working at all.

  Baseline

• Hospital anxiety and depression scale (HADS)

  Self-assessment of anxiety and depression. Consists of two scales measuring the probability of having anxiety and depression respectively. Min score 0, max 21 for each scale. Higher scores indicate higher probability of anxiety/depression.

  Baseline

• WHO-5 Well-Being Index

  Overall rating of well-being. The WHO-5 score range is a raw score of 0-25, which is then multiplied by 4 to get a percentage score of 0-100. Higher score indicates higher well-being.

  Baseline

• Brief index of job satisfaction (BIAJS)

  The Brief Index of Affective Job Satisfaction (BIAJS) has a score range of 1 to 5 for each of its four items, based on a 5-point Likert scale where 1 is "strongly disagree" and 5 is "strongly agree". The total BIAJS score is the sum of these four items, resulting in a possible range from 4 to 20, with higher scores indicating greater affective job satisfaction.

  Baseline

Secondary Outcomes (2)

• Work-life balance

  Baseline

• Can-Work-S

  Baseline

Study Arms (1)

Patients with MS and of working age (18-65) who have been referred to neuropsychological evaluation.

Time of neuropsychological assessment from 5 years before until study start.

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients of working age with MS in Region Gävleborg who have performed a neuropsychological assessment during the 5 years prior to study start and who are not suffering from other diagnosis which impact their work ability to a large extent.

You may qualify if:

• Multiple sclerosis Age between 18-65 Performed a neuropsychological assessment at the Neurology department at Gävle Hospital during the last 5 years (counting from study start) -

You may not qualify if:

• Other diagnosis hindering work participation more than MS

Sponsors & Collaborators

• Region Gävleborg: lead
• University of Gavle: collaborator

Study Sites (1)

Gävle hospital

Gävle, Sweden

Location

MeSH Terms

Conditions

Multiple Sclerosis

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases

Central Study Contacts

Natascha Ekdahl

CONTACT

+4626278023; natascha.ekdahl@regiongavleborg.se

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 22, 2025
• First Posted: October 8, 2025
• Study Start: April 1, 2026
• Primary Completion (Estimated): November 1, 2026
• Study Completion (Estimated): November 1, 2026
• Last Updated: October 8, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

SE (1)